Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Wholesaler Arguments Against Rx Pedigree Papers “Weak” – Fla. Grand Jury

Executive Summary

Wholesalers' arguments against requirements to maintain prescription drug pedigree documents are "weak and unpersuasive," an interim report from Florida's Seventeenth Statewide Grand Jury states

You may also be interested in...



Florida Pedigree Enforcement For 30 “Specified” Drugs Begins Sept. 1

Pfizer's cholesterol-lowering drug Lipitor could be one of the first additions to a list of 30 drugs with new "pedigree" paper requirements in Florida

Florida Pedigree Enforcement For 30 “Specified” Drugs Begins Sept. 1

Pfizer's cholesterol-lowering drug Lipitor could be one of the first additions to a list of 30 drugs with new "pedigree" paper requirements in Florida

Florida wholesaler investigation

A Florida grand jury investigation into "gray market" transactions is not relevant to the big three wholesalers, McKesson and AmerisourceBergen told the SG Cowen meeting in Boston. "I don't think this investigation included wholesalers as you would know them," McKesson CEO John Hammergren said. "There's about 400 wholesalers apparently in Florida because there's some loopholes in the laws down there." The grand jury urged adoption of PDMA "pedigree" requirements to cut off counterfeiting and other problems with secondary distributors (1"The Pink Sheet" March 17, p. 26)...

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS041453

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel